聚合酶ε(POLE)突变在高级别子宫内膜样子宫内膜癌中的预后:系统综述与荟萃分析
该系统综述与荟萃分析纳入19项研究共3092例高级别子宫内膜样子宫内膜癌患者,评估POLE突变与总生存(OS)和无进展生存(PFS)的关联。POLE突变患者死亡风险较低(HR=0.36, 95%CI 0.26-0.50, I²=0%, 10项试验),疾病进展风险较低(HR=0.31, 95%CI 0.17-0.57, I²=33%, 10项试验)。POLE突变合并患病率为11%(95%CI 9-13, I²=68%, 18项研究)。
要点
- 高级别子宫内膜样子宫内膜癌中POLE突变患者死亡风险较低(HR=0.36, 95%CI 0.26-0.50)。
- POLE突变患者疾病进展风险较低(HR=0.31, 95%CI 0.17-0.57)。
- POLE突变合并患病率为11%(95%CI 9-13)。
核心结论
- 高级别子宫内膜样子宫内膜癌中POLE突变与更有利的预后相关,总生存和无进展生存均提高。
研究设计与样本
- 系统综述与荟萃分析,遵循PRISMA指南(PROSPERO注册号CRD4202340008),检索PubMed/Medline、EMBASE、Cochrane Library、Scopus和Web of Science数据库,纳入19项研究共3092例高级别子宫内膜样子宫内膜癌患者,采用一阶段和两阶段方法、Kaplan-Meier法及Cox比例风险模型分析OS和PFS。
主要发现
- POLE突变患者死亡风险较低(HR=0.36, 95%CI 0.26-0.50, I²=0%, 10项试验)。
- POLE突变患者疾病进展风险较低(HR=0.31, 95%CI 0.17-0.57, I²=33%, 10项试验)。
- POLE突变合并患病率为11%(95%CI 9-13, I²=68%, 18项研究)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: POLE mutated endometrial carcinomas may represent a subspecific type of tumors harboring a more favorable prognosis. Grade 3 (G3 or high-grade) endometrioid endometrial carcinomas remain a clinical dilemma, with some tumors behaving as the low-grade counterparts and others presenting a more aggressive behavior. OBJECTIVES: To determine the association between POLE mutational status and the overall-survival (OS) and progression-free-survival (PFS) of patients with G3 endometrioid endometrial cancer (EC). We also aimed to determine the prevalence of POLE mutations in G3 endometrioid EC. METHODS: We conducted a systematic review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (PROSPERO No: CRD4202340008). We searched the following electronic databases: PubMed/Medline, EMBASE, Cochrane Library, Scopus, and Web of Science. For time-to-event data, the effect of POLE mutation in G3 EC was described using hazard ratios (HRs) and corresponding 95% confidence intervals (CIs). Individual patient data for each study was investigated if available from the study authors. If individual patient data were not available, information regarding time-to-event outcomes was extracted using an appropriate methodology. OS and PFS were analyzed using both one-stage and two-stage approaches, the Kaplan-Meier method, and Cox-proportional hazards models. RESULTS: This systematic review and meta-analysis included 19 studies with 3092 patients who had high-grade endometrioid EC. Patients with POLE mutations had lower risks of death (HR = 0.36, 95% CI 0.26 to 0.50, I2 = 0%, 10 trials) and disease progression (HR = 0.31, 95% CI 0.17 to 0.57, I2 = 33%, 10 trials). The pooled prevalence of POLE mutation was 11% (95% CI 9 to 13, I2 = 68%, 18 studies). CONCLUSION: POLE mutations in high-grade endometrioid EC are associated with a more favorable prognosis with increased OS and PFS.
引用
- Casanova J, Duarte GS, da Costa AG, et al. Prognosis of polymerase epsilon (POLE) mutation in high-grade endometrioid endometrial cancer: Systematic review and meta-analysis. Gynecol Oncol. 2024. PMID: 38262245. doi:10.1016/j.ygyno.2024.01.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。